118 related articles for article (PubMed ID: 38686798)
1. Clinical impact of skeletal muscle mass change during the neoadjuvant chemotherapy period in patients with gastric cancer: An ancillary study of JCOG1002.
Sato R; Tokunaga M; Mizusawa J; Sato Y; Ito S; Takahari D; Sano T; Onaya H; Yoshikawa T; Boku N; Terashima M
World J Surg; 2024 Jan; 48(1):163-174. PubMed ID: 38686798
[TBL] [Abstract][Full Text] [Related]
2. Skeletal muscle loss after total gastrectomy, exacerbated by adjuvant chemotherapy.
Yamaoka Y; Fujitani K; Tsujinaka T; Yamamoto K; Hirao M; Sekimoto M
Gastric Cancer; 2015 Apr; 18(2):382-9. PubMed ID: 24715254
[TBL] [Abstract][Full Text] [Related]
3. Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil.
Matsunaga T; Saito H; Miyauchi W; Shishido Y; Miyatani K; Morimoto M; Murakami Y; Hanaki T; Kihara K; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Fujiwara Y
BMC Cancer; 2021 Nov; 21(1):1219. PubMed ID: 34774016
[TBL] [Abstract][Full Text] [Related]
4. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
[TBL] [Abstract][Full Text] [Related]
5. Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro-oesophageal cancer.
den Boer RB; Jones KI; Ash S; van Boxel GI; Gillies RS; O'Donnell T; Ruurda JP; Sgromo B; Silva MA; Maynard ND
BJS Open; 2020 Oct; 4(5):847-854. PubMed ID: 32841538
[TBL] [Abstract][Full Text] [Related]
6. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
[TBL] [Abstract][Full Text] [Related]
7. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
Tan BH; Brammer K; Randhawa N; Welch NT; Parsons SL; James EJ; Catton JA
Eur J Surg Oncol; 2015 Mar; 41(3):333-8. PubMed ID: 25498359
[TBL] [Abstract][Full Text] [Related]
8. Correlation between Skeletal Muscle Mass and Adverse Events of Neoadjuvant Chemotherapy in Patients with Gastric Cancer.
Matsuura N; Motoori M; Fujitani K; Nishizawa Y; Komatsu H; Miyazaki Y; Miyazaki S; Tomokuni A; Komori T; Iwase K
Oncology; 2020; 98(1):29-34. PubMed ID: 31509833
[TBL] [Abstract][Full Text] [Related]
9. Cardiopulmonary exercise testing has greater prognostic value than sarcopenia in oesophago-gastric cancer patients undergoing neoadjuvant therapy and surgical resection.
West MA; Baker WC; Rahman S; Munro A; Jack S; Grocott MP; Underwood TJ; Levett DZ;
J Surg Oncol; 2021 Dec; 124(8):1306-1316. PubMed ID: 34463378
[TBL] [Abstract][Full Text] [Related]
10. Body composition parameters predict pathological response and outcomes in locally advanced gastric cancer after neoadjuvant treatment: A multicenter, international study.
Lin JX; Tang YH; Zhou WX; Desiderio J; Parisi A; Xie JW; Wang JB; Cianchi F; Antonuzzo L; Borghi F; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Staderini F; Marano A; Peluso C; Li P; Zheng CH; Ma YB; Huang CM
Clin Nutr; 2021 Aug; 40(8):4980-4987. PubMed ID: 34364237
[TBL] [Abstract][Full Text] [Related]
11. Impact of Preoperative Skeletal Muscle Quality Measurement on Long-Term Survival After Curative Gastrectomy for Locally Advanced Gastric Cancer.
Waki Y; Irino T; Makuuchi R; Notsu A; Kamiya S; Tanizawa Y; Bando E; Kawamura T; Terashima M
World J Surg; 2019 Dec; 43(12):3083-3093. PubMed ID: 31482345
[TBL] [Abstract][Full Text] [Related]
12. Optimal Cutoff Values of Skeletal Muscle Index to Define Sarcopenia for Prediction of Survival in Patients with Advanced Gastric Cancer.
Nishigori T; Tsunoda S; Obama K; Hisamori S; Hashimoto K; Itatani Y; Okada K; Sakai Y
Ann Surg Oncol; 2018 Nov; 25(12):3596-3603. PubMed ID: 30167910
[TBL] [Abstract][Full Text] [Related]
13. Skeletal muscle loss is an independent negative prognostic factor in patients with advanced lower rectal cancer treated with neoadjuvant chemoradiotherapy.
Takeda Y; Akiyoshi T; Matsueda K; Fukuoka H; Ogura A; Miki H; Hiyoshi Y; Nagasaki T; Konishi T; Fujimoto Y; Fukunaga Y; Ueno M
PLoS One; 2018; 13(4):e0195406. PubMed ID: 29630652
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of CT-determined sarcopenia in patients with advanced gastric cancer.
Lee JS; Kim YS; Kim EY; Jin W
PLoS One; 2018; 13(8):e0202700. PubMed ID: 30125312
[TBL] [Abstract][Full Text] [Related]
15. Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer.
Motoori M; Fujitani K; Sugimura K; Miyata H; Nakatsuka R; Nishizawa Y; Komatsu H; Miyazaki S; Komori T; Kashiwazaki M; Iwase K; Yano M
Oncology; 2018; 95(5):281-287. PubMed ID: 30149394
[TBL] [Abstract][Full Text] [Related]
16. Skeletal Muscle Mass Depletion After Gastrectomy Negatively Affects the Prognosis of Patients With Gastric Cancer.
Kanazawa Y; Yamada T; Kakinuma D; Matsuno K; Ando F; Fujita I; Kanno H; Kato S; Yoshida H
Anticancer Res; 2020 Aug; 40(8):4271-4279. PubMed ID: 32727754
[TBL] [Abstract][Full Text] [Related]
17. Clinical effect of enteral nutrition support during neoadjuvant chemotherapy on the preservation of skeletal muscle mass in patients with esophageal cancer.
Kita R; Miyata H; Sugimura K; Tanaka K; Makino T; Yamashita K; Yamasaki M; Motoori M; Shiraishi O; Kimura Y; Yasuda T; Yano M; Doki Y
Clin Nutr; 2021 Jun; 40(6):4380-4385. PubMed ID: 33526287
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Impact of the Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy on Older Patients with Esophageal Cancer.
Harada T; Tsuji T; Ueno J; Koishihara Y; Konishi N; Hijikata N; Ishikawa A; Kotani D; Kojima T; Fujiwara H; Fujita T
Ann Surg Oncol; 2022 Dec; 29(13):8131-8139. PubMed ID: 35978207
[TBL] [Abstract][Full Text] [Related]
19. Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study.
Järvinen T; Ilonen I; Kauppi J; Salo J; Räsänen J
World J Surg Oncol; 2018 Feb; 16(1):27. PubMed ID: 29433514
[TBL] [Abstract][Full Text] [Related]
20. The impact of neoadjuvant chemotherapy on skeletal muscle depletion and preoperative sarcopenia in patients with resectable colorectal liver metastases.
Eriksson S; Nilsson JH; Strandberg Holka P; Eberhard J; Keussen I; Sturesson C
HPB (Oxford); 2017 Apr; 19(4):331-337. PubMed ID: 28089364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
